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Abstract 
The CD28 costimulatory receptor has a pivotal role in T cell biology as this molecule 
amplifies T cell receptor (TCR) signals to provide an efficient immune T cell response. There 
is a large debate about how CD28 mediates these signals. Here, we designed a CD28 gene 
targeted knock-in mouse strain lacking the cytoplasmic tail of CD28. As is the case in CD28-
deficient (CD28 knock-out) mice, regulatory T cell homeostasis and T cell activation are 
altered in these CD28 knock-in mice. Unexpectedly, the presence of a CD28 molecule 
deprived of its cytoplasmic tail could partially induce some early activation events in T cells 
such as signaling events or expression of early activation markers. These results unravel a 
new mechanism of T cell costimulation by CD28, independent of its cytoplasmic tail.    
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Introduction   
Costimulatory molecules are essential to achieve complete T cell activation. CD28 is a 
founding member of the costimulatory receptor family [1]. A large number of experiments 
have been performed to assess the role of the cytoplasmic tail of this molecule including 
studies using primary T cells in transgenic (Tg) mice or retroviral reconstitution on the CD28-
deficient background [2,3]. In these experiments, CD28 expression is under control of a 
heterologous promoter, and not under endogenous control.  
Several signaling motifs can be identified in the cytoplasmic tail  of CD28. One of the 
strategies used to investigate the importance of the CD28 cosignaling has been to generate 
tail-less CD28 mutants defective in signaling on a CD28 null background. Such CD28 mutant 
were expressed using the human CD2 promoter in CD28-deficient mice; cell surface 
expression of the transgene was detected on splenic T cells at levels higher than those from 
WT mice [4]. Tail-less CD28 Tg T cells were shown to be functional in terms of cytokine 
production and proliferation, to be insensitive to CD28 engagement via CD28 mAbs or via 
B7-transfected CHO cells. These findings have been confirmed by retroviral infection of these 
tail-less mutants in CD28-deficient T cells [5,6].  
However, studies of TCR Tg T cells from CD28-deficient mice expressing a tail-less CD28 
mutant showed that the CD28 cytoplasmic tail is important for the recruitment of signaling 
molecules but not required for CD28 clustering at the T cell surface [7]. This tail-less CD28 
receptor clustering has been described to play a regulatory function in the initial steps of T 
cell activation. In addition to inducing signaling events via its cytoplasmic tail, CD28 surface 
expression facilitates some TCR-induced signaling events during cell-cell interactions [8]. To 
study the role of CD28 in adhesion versus signaling in naive T cells where CD28 expression 
is controlled by endogenous elements, we designed a mouse strain lacking the cytoplasmic 
tail of CD28, tail-less CD28 gene targeted knock-in mouse (termed CD28 KI). This new 
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mouse strain allows the analysis of the role of CD28 on T cells allow to exclude specifically, 
independent of signaling via its cytoplasmic tail. Here, we analyze the influence of the loss of 
the entire CD28 cytoplasmic tail on T cell activation and the incidence on bacterial infections. 
In other words, does CD28 ligation induce signal events in the absence of its cytoplasmic tail? 
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Materials and methods 
Animals 
CD28-deficient mice (CD28 KO), described previously [9], were bred onto a B6 background 
and were maintained in our animal facility. C57BL/6 (B6) and BALB/c mice were purchased 
from Charles River Laboratories (L’Arbresle, France) and Janvier Labs SAS (Le Genest St 
Isle, France). All mice used were cared for in accordance with institutional guidelines. All 
experimental
 
protocols were in agreement with the French Guidelines for animal handling and 
were approved by the Inserm ethical committee. 
 
Gene targeting and generation of tail-less CD28 knock-in mice 
Tail-less CD28 knock-in (KI) mice (CD28 N163* also termed CD28 KI) were generated in 
the laboratory (Figure S1A). A targeted mutagenesis in the exon 4 of cd28 allowed the 
substitution of an asparagine codon (N163) by a stop codon. A neomycin selection cassette 
surrounded by loxP sites and a thymidine kinase cassette were introduced. The recombination 
vector was electroporated into embryonic stem (ES) cells of 129/Sv mice. After dual 
selection, ES cells were injected into blastocytes of C57BL/6 cells mice by Service 
d’Expérimentation Animale de Transgénèse et de Recombinaison Homologue (SEAT/UPS 44 
CNRS, Villejuif, France). Chimeric males were mated with Cre-transgenic mice, in order to 
generate heterozygous mice without the
 
neomycin selection cassette. Genotype analyses were 
performed on
 
genomic DNA from tail biopsies with PCR primers F 
(5’AAGGCTCCTCAGGGTCATTT3’) and R (3’GCTGGTAAGGCTTTCGAGTG5’). Mice 
heterozygous for the deletion on a mixed 129/Sv by C57BL/6
 
background were intercrossed 
to generate homozygous CD28 KI mouse strain. Tail-less CD28 KI mouse strain were 
backcrossed with C57BL/6 cells mice at least 10 times.  
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Antibodies 
MAbs with the following specificities were used for flow cytometry (FCM): CD3ε (clone: 
145-2C11), CD4 (clone: RM4-5), CD8 (clone: 53-6.7), CD25 (clone: PC61.5), CD28 
(clone: 37.51), CD44 (clone: IM7), CD69 (clone: H1.2F3), H-2Kb (clone: AF6-88.5.5.3) and 
FoxP3 (clone: FJK-16s) (all eBioscience, Paris, France), CD127 (clone: A7R34) (Biolegend, 
San Diego, CA, USA), anti-TCR Vβ6 (clone: RR4-7) and anti-TCR Vβ8.1/8.2 (clone: 
MR5.2) (BD Biosciences, Le Pont-De-Claix, France). A chimeric antibody CD80-Ig was used 
to determined CD28 affinity for its ligand CD80 (R&D Systems, Lille, France). Goat 
polyclonal anti-CD28 biotinylated antibodies were used for immunoblotting (R&D Systems, 
Lille, France).  
 
Flow cytometry (FCM) analysis 
Cells were washed twice in FCM buffer (PBS, 2% FCS, 1mM EDTA, 0.02% NaN3). Cell 
number was determined by Trypan blue staining. From 2.5 x 10
5 
to 10
6
 cells were then 
incubated with conjugated-antibodies for 30 min at 4°C, washed twice with FCM buffer and 
fixed with 4% paraformaldehyde. For intracellular staining, cells were permeabilized and 
fixed with Cytofix/Cytoperm (BD Biosciences, Le Pont-De-Claix, France), incubated with 
conjugated antibodies for 30 min at 4°C and washed twice with Permwash buffer (BD 
Biosciences, Le Pont-De-Claix, France). All data were acquired on an FACS LSR II SORP 4 
lasers flow cytometer (Becton Dickinson, Le Pont-De-Claix, France) and analyzed with 
FlowJo software (Tree Star, Ashland, OR, USA). 
 
T cell activation 
For CD3/CD28 stimulation, 2.5 x 10
5
 CD4
+
 T cells isolated from the spleen were mixed (ratio 
1:1) with Dynabeads Mouse CD3/CD28 T Cell Expander (Life Technologies, Cergy-
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Pontoise, France) in 96-well round bottom plates (200 µL) and incubated for 3 days (37°C, 
5% CO2) with recombinant IL-2 (60 U/mL). For staphyloccoccal enterotoxin B (SEB; Sigma 
Aldrich Chemie S.a.r.l., L'isle d'Abeau Chesnes, France) stimulation, SEB was dissolved in 
sterile phosphate buffered saline (PBS) at 1 mg/ml and further dilutions were done in RPMI-
1640 media supplemented with 10 % FCS. 5 x 10
5
 splenocytes were incubated for 24 hrs with 
different concentraions of SEB in 96-well round bottom plates. For allogeneic stimulation, 
BALB/c mouse splenocytes were pre-activated for 24 hrs with LPS (10 µg/mL). Then, 2.5 x 
10
5
 CD4
+
 T cells were mixed (ratio 1:3) with 7.5 x 10
5
 BALB/c mouse splenocytes irradiated 
with 50Gy as antigen presenting cells (APCs) and incubated for 3 or 4 days with recombinant 
IL-2 (60 U/mL). For PMA/ionomycin stimulation, 2.5 x 10
5
 CD4
+
 T cells
 
were incubated for 
3 to 4 days with 10 ng/mL phorbol myristate acetate and 1 µg/mL ionomycin. Activation was 
assessed by FACS analysis for activation markers expression at the cell surface and by ELISA 
(eBioscience, Paris, France) for IFN- production. 
 
Regulatory T cell stimulation 
CD4
+
 cells were obtained by antibody-mediated magnetic bead depletion from lymph nodes 
or spleen (Miltenyi Biotec, Paris, France). Purity was checked by FCM and was always more 
than 97%. For regulatory T cell stimulation, 10
5
 splenocytes were mixed (ratio 1:2) with 
Dynabeads Mouse CD3/CD28 T Cell Expander and were incubated for 72h (37°C, 5% CO2) 
with recombinant IL-2 (1 µg/mL corresponding to 10
5
 units/mL) and TGF- (1 ng/mL) 
purchased from R&D Systems (Lille, France). Regulatory T cell stimulation was assessed by 
FACS analysis. 
 
Phosphoflow by FACS analysis  
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Cells were stimulated 5-30 min with Dynabeads Mouse CD3/CD28 T Cell Expander and 
recombinant IL-2 (10ng/mL). Phosphoflow analysis was then performed by cytometry as 
previously described [10]. Briefly, cells were fixed and permeabilized, incubated with anti-
phospho-Akt S473 or anti-phospho-ERK-1/2 T202/Y204 mAbs (Cell Signaling Technology, 
Danvers, MA, USA) and appropriate biotinylated secondary antibodies. Finally, revelation 
was performed using Streptavidin-phycoerythrin solution (Beckman Coulter, Roissy, France). 
All data were acquired by FACS analysis. 
 
Bacterial preparation, mice inoculation and antibodies response analysis 
Coxiella burnetii RSA493 Nine Mille strain was cultured in L929 cell line as previously 
reported [11]. Monolayers of L929 cells were infected for 7 to 10 days and bacteria were 
harvested, sonicated and quantified by Gimenez stain. Bacterial viability was assessed using 
the LIVE/DEAD BacLight kit (Molecular Probes) as previously reported [11]. Wild type 
(WT), CD28 KO and CD28 KI mice housed in biosafety level 3 laboratory were inoculated 
with 5x10
5
 bacteria per mouse using intra-peritoneal route (i.p.). Whole blood specimens were 
sampled by retro-orbital puncture at days 14 and 21 post-inoculation (pi) (n = 5 for WT and 
KO mice and n = 4 for KI mice) for serology experiments (see below). Serum was obtained 
by centrifugation of blood from infected mice at 700g for 10 min. Obtained serum was stored 
at –80°C until analysis for the presence of specific antibodies anti- C. burnetii. Smears of C. 
burnetii antigens methanol-fixed were incubated with serial dilutions of serum for 30 min at 
37°C. After washing, the presence of immunoglobulins G (IgG) against C. burnetii was 
revealed using fluorescein-conjugated goat antibodies (Abs) directed against mouse IgG 
diluted at a 1:400. The samples were titered by the end point. 
 
Statistical analysis 
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Results shown represent means ± SD. Statistical analysis was performed with Student and 
ANOVA tests using Prism software (La Jolla, CA, USA).  
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Results  
Characterization of CD28 tail-less KI mice 
 To address the role of the CD28 cytoplasmic tail in T cell activation, we generated CD28 tail-
less KI (CD28 KI) mice. This truncated CD28 protein, CD28 tail-less (CD28 TL) contains the  
first 162 residues and lacks the intracellular domains involved in the binding to signaling 
molecules (Figure 1A). CD28 surface expression in CD28 KI thymocytes is similar to WT 
thymocytes (Figure S1B). By western blot, we assessed the molecular weight of CD28 TL, 
which is lower than that of CD28 WT (Figure S1C). The CD28 extracytoplasmic Ig domain 
binds to the CD80 and CD86 ligands. CD80-Fc (Figure S1D) and CD86-Fc (data not shown) 
fusion proteins bind similarly to the surface of thymocytes from CD28 KI or WT mice. As 
reported for CD28 KO mice [9], analysis of CD4/CD8, CD25/CD44 and H-2Kb/CD69 
fractions in thymus showed no major difference in T cell development between CD28 KI and 
WT mice (Figure S1E-G). Moreover, CD28 KI splenocytes were analyzed for their surface 
expression of CD28 (Figure 1A), showing no difference compared to WT cells. Thus, the 
truncated CD28 receptor is normally expressed at the surface of the CD28 KI T cells and is 
recognized by its natural ligands B7.  
 
CD28 tail-less (CD28 TL) engagement can amplify T cell signals during T cell 
costimulation  
In the context of TCR crosslinking, CD28 ligation induces an optimal activation of signaling 
pathways such as PKB/Akt and ERK-1/2 activation [12]. Using phosphoflow analysis, we 
analyzed the phosphorylation of Akt (Ser-473) and ERK-1/2 (Thr-202 / Tyr-204) from CD4
+
 
T cells both in CD25
-
 or CD25
high
 subtypes. Cells were stimulated with CD3/CD28 beads and 
phosphorylation was measured as fold induction compared to untreated control. As expected, 
Akt and ERK-1/2 phosphorylation was higher in CD25
high
 cells than CD25
-
 cells (Figure 1B).  
Phosphorylation rates in CD28 KI cells were intermediate between CD28 KO and WT cells: 
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respectively for Akt 1.74  0.05, 1.15  0.10 and 1.86  0.06, and for ERK-1/2 1.85  0.14, 
1.30  0.21 and 2.32  0.16 (CD25high cells with 30 min CD3/CD28 stimulation). These 
results show that CD28 lacking its cytoplasmic tail, is able to significantly increase the TCR 
activation signal by activation of PI3K-Akt and MAPK pathways.  
 
Late T cell activation events are less impaired in CD28 KI than in CD28 KO T cells 
CD4
+
 T cells isolated from the three different mouse strains were stimulated with CD3/CD28 
beads for 3 days. The percentage of activated T cells corresponding to CD69
POS
 or CD44
POS
 
cells (Figure 2A & 2B, left panels) was measured and production of IFN- was evaluated 
(Figure 2C). Similar results were obtained in CD28 KO and CD28 KI conditions for CD69 
expression (Figure 2A), however the percentage of CD44
 POS
 cells in CD28 KI is higher than 
CD28 KO T cells (Figure 2B). The detection of another activation marker, CD25 shows 
similar results in that CD28 KI appears at an intermediate range between CD28 KO and WT 
conditions (Figure S2B). This difference is mainly due to a difference in the percentage of 
cells with a low level of CD25 expression (Figure S2C). The percentage of cells with a high 
level of CD25 expression (Figure S2D) is very low both in CD28 KI and CD28 KO T cells. 
As this high CD25
+
 population could be due to a endogenous IL-2 stimulation, this suggests 
that both CD28 KI and CD28 KO T cells are defective for the production of this cytokine. 
Therefore, upon CD3/CD28 beads stimulation, IFN- production is reduced both in CD28 KI 
and CD28 KO T cells (Figure 2C). By phospho-Akt flow analysis, a PI3K/Akt signaling 
induction is detected in CD4
+
 T cells from CD28 KI mice (Figure 1B). The loss of IL-7R 
(CD127) expression was reported as a hallmark of PI3K activation in effector CD4
+
 T cells 
[13]. Therefore, the percentage of CD127
POS
 cells was measured in CD4
+
 T cells from lymph 
nodes of the different mouse strains (Figure S3). Upon CD3/CD28 T cell stimulation, the 
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percentage of CD127
POS
 cells is lower in WT than in CD28 KO mice and CD28 KI condition 
has an intermediate phenotype.  
Using a bacterial superantigen such as Staphylococcal enterotoxin B (SEB) to activate T cells, 
Similar results were obtained in CD28 KO and CD28 KI conditions for CD69 expression 
(Figure S4). Furthermore, CD4
+
 T cells were also stimulated by irradiated BALB/c 
splenocytes as antigen presenting cells (APC) for 3 or 4 days, then activation marker 
expression (CD69 and CD44) were measured by flow cytometry (Figure 2A & 2B). No 
significant increase of CD69 and CD44 expression level was detected at day 3 either in CD28 
KI or in CD28 KO T cells (Figure 2A & 2B, left panels). However, at day 4 post-
allostimulation, CD28 KI T cells showed an intermediate induction phenotype compared to 
CD28 KO and WT cells (Figure 2A & 2B, right panels). These results show that the 
cytoplasmic tail of CD28 is required to induce functional costimulatory events in primary T 
cells. However, in some cases, signaling events induced by CD28 engagement occur in 
absence of its cytoplasmic tail.   
 
The CD28 cytoplasmic tail is required for regulatory T cells homeostasis 
CD28 costimulation by its ligands CD80/CD86 is essential for regulatory T cells (Tregs) 
homeostasis and Treg subset is strongly decreased in CD28 KO mice [14]. The presence of 
CD25
+
/FoxP3
+ 
Tregs was measured in splenocytes from the three different mouse strains 
(Figure 3A, left panel). As was observed in CD28 KO, CD28 KI mice showed a clear 
reduction of  CD25
+
/FoxP3
+
 cells compared to WT mice. We used a Treg stimulation assay to 
induced Treg differentiation and proliferation. By focusing on regulatory CD25
+
/FoxP3
+ 
subset, we obtained a strong decrease in CD28 KI similar to CD28 KO, compared to WT cells 
(respectively 4.52  0.53, 6.44  0.62 and 15.05  1.45) (Figure 3A, right panel). However, in 
the same assay, the total CD25
+
 T cell population corresponding mainly to activated effector 
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T cells is decreased in CD28 KO, but not in CD28 KI conditions (Figure 3B). The results 
suggest that the cytoplasmic tail of CD28 is mandatory for Treg homeostasis and activation, 
but not for effector T cell activation. 
 
The cytoplasmic tail of CD28 is required to drive an optimal IgG production during 
Coxiella burnetii infection 
Q fever is a zoonosis caused by Coxiella burnetii, an obligate intracellular microorganism that 
replicates in myeloid cells. The development of a protective immune response against C. 
burnetii requires an adaptive immune response as shown by Honstettre et al. [15]. Despite the 
fact that the CD28 gene inactivation in mice leads to a decrease of IgG production, it also 
leads to a decrease of C. burnetii burden in tissues [16]. We analyzed the CD28 KI mice 
immune response to infection by C. burnetii. There were no significant differences in C. 
burnetii burden in both blood and spleen compared to CD28 KO mice, but we found an 
increased burden in liver (Figure 4A). IgG production was assessed and we found a large 
decrease of Igs both in CD28 KI and CD28 KO mice compared to B6 (WT) mice. Ig titers are 
slightly but significantly higher in CD28 KI than in CD28 KO mice at 14 days, but then this 
decrease is comparable in CD28 KO and in CD28 KI mice, 21 days after infection by C. 
burnetii (Figure 4B). These results prove that the cytoplasmic tail of CD28 is required to drive 
an optimal IgG production during C. burnetii infection.  
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Discussion 
The CD28 receptor has been identified as a costimulatory molecule that can amplify TCR-
driven signals to induce functional events in T cells. Several partners have been identified to 
be associated to the cytoplasmic tail of CD28 [2,17], and we contributed to identify some of 
them such as the phosphatidylinositol 3’-kinase (PI3K) and some protein tyrosine kinases 
[18,19]. In order to precisely define the relative importance of each individual signaling motif 
in the CD28 sequence, some CD28 gene targeted KI mouse strains have been generated 
[20,21]. Despite the description of these elegant mouse models, in 2010, J. Boomer and J. 
Green entitled their review article in the Cold Spring Harbor Perspectives in Biology, “An 
enigmatic tail of CD28 signaling” [2]. Previous data assessing the function of tail-less version 
of CD28 have been performed using retroviral transfer into previously activated cells (which 
cannot achieve T cell development and activation of naïve T cells) or using transgenic CD28 
which is generally overexpressed compared to the endogenous CD28 expression levels. In this 
context, we generated a mouse strain lacking the entire cytoplasmic tail of CD28, tail-less 
CD28 gene targeted KI mouse. In contrast to the previously described CD28 tail-less models, 
CD28 engagement delivers some co-signals in CD28 tail-less KI T cells, suggesting that 
CD28 allows partial amplification of TCR signals in the absence of its cytosolic tail. How an 
adhesion molecule expressed at the T cell surface can participate to the T cell costimulatio is 
still a matter of debate [22]. 
Expression of the CD28 receptor and its ability to recognize B7 ligands are similar in 
C57BL/6 mice and CD28 KI animals. T cell homeostasis is well described in CD28 KO mice, 
where the numbers of effector T cells are normal but associated to a dramatic decrease of 
Tregs [9,14]. The overall T cell phenotype of the CD28 KI mouse strain is similar to the 
CD28 KO model, showing that the cytoplasmic tail of CD28 is mandatory for Treg 
development. Moreover, in both CD28 KO and CD28 KI mice, T cell responses are impaired 
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for activation marker expression, IFN- secretion or IgG production during bacterial infection. 
Unexpectedly, some differences appear between CD28 KO and CD28 KI mice, when T cell 
activation in effector T cells is assessed. In the context of TCR+CD28 costimulation, the 
magnitude of signaling events induced in CD28 KI T cells is always lower than WT T cells, 
but significantly higher than in CD28 KO T cells where by definition the CD28 molecule is 
not expressed. These results suggest that the engagement of the CD28 molecule is able to 
amplify TCR signaling at least partially via the presence of the CD28 costimulatory receptor 
at the plasma membrane.  
The lipid kinase, PI3K that directly binds to the cytoplasmic tail of CD28 [18], can be 
triggered via CD28 in the absence of a direct binding to the YxxM CD28 binding motif [23]. 
However, these observations do not exclude an indirect binding to the cytoplasmic tail. Here, 
we showed that in the context of TCR engagement, stimulation of CD28 can promote 
PI3K/Akt signaling in absence of its entire cytoplasmic tail. Bacterial superantigens can 
trigger T cell activation; these potent T cell activation inducers can create a bridge between 
TCR and CD28 receptor at the T cell surface to facilitate T cell signaling [24]. CD28 
triggering can enhance the PI3K/Akt signaling pathway in T cells when this receptor is 
located in specialized plasma membrane structures called raft nanodomains [25]. This specific 
membrane localization of CD28 followed by a receptor aggregation induced via its 
engagement, is able to promote the TCR cell signaling. Before the engagement of signaling 
proteins with the cytoplasmic tail, receptor oligomerization and plasma membrane 
sublocalization could represent the initial step of the costimulation events induced by CD28. 
It is well established that aggregation of receptors at the T cell surface is a potent mechanism 
to induce cell signaling events [26]. Among the signaling proteins associated with CD28 
signaling [2], the Src-family protein tyrosine kinase member Lck is anchored to the inner 
phase of the plasma membrane and is a resident of the lipid rafts. The CD28 molecule could 
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deliver a trans-signal to the TCR in naive primary T cells to prime TCR signaling. In this 
case, the CD28 molecule in the absence of its cytosolic tail could participate to TCR-mediated 
signals in a quantitative-manner by increasing TCR clustering and/or lipid raft coalescence 
[27]. One hypothesis in favour of a qualitative costimulatory model would be that the 
transmembrane domain of CD28 could be associated with unknown protein binding partners 
involved in cell signaling and/or cytoskeleton reorganization.  
Taken together, our results show that the cytoplasmic tail of CD28 is mandatory for Treg 
development and is required to promote a full activation of effector T cells. However, in the 
absence of its cytoplasmic tail, CD28 can also induce some signaling events. These initial 
steps of cosignaling at the plasma menbrane should be further investigated. It is important to 
understand the behaviour of these cosignaling molecules when there are recognized by a 
ligand as a monomer or an oligomer, as therapeutic strategies using monoclonal antibodies 
have been designed to target cosignaling molecules [17].  
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Figure legends 
 
Figure 1. Analysis of signaling events induced by CD28 triggering in CD28 tail-less (CD28 
KI) T cells. (A) Peptide sequence corresponding to the deleted CD28 cytoplasmic region in 
CD28 KI mouse strain. Expression of CD28 measured by flow cytometry in CD4
+
 T cells 
from spleen of WT, CD28 KO and CD28 KI mice. (B) Phosphorylation induction of signaling 
key molecules, Akt (S473) and ERK-1/2 (T202/Y204) measured by phosphoflow in 
CD4
+
/CD25
-
 and CD4
+
/CD25
-
 cell subsets after CD3/CD28 beads stimulation of splenocytes 
from WT, CD28 KO and CD28 KI mice. Representative data from 3 independent experiments 
(n= 8-9 mice each genotype/experiment, mean ± SD), * P < 0.05.  
 
Figure 2.  Ex vivo stimulation of CD28 tail-less (CD28 KI) CD4
+
 T  cells. Isolated CD4
+
 T 
cells from spleen of WT, CD28 KO and CD28 KI mice were stimulated for 3 or 4 days.(A) 
Expression of CD69 activation marker measured by flow cytometry upon 3 days (left panel) 
or 4 days (right panel) of stimulation. (B) Expression of CD44 activation marker measured by 
flow cytometry upon 3 days (left panel) or 4 days (right panel) of stimulation. (C) IFN-γ 
accumulation is measured by ELISA following the 3 days of CD3/CD28 beads stimulation. 
Representative data from 2 independent experiments (n= 6 - 7 mice each 
genotype/experiment, mean ± SD), *** P < 0.001; **P < 0.01 and *P < 0.05.   
 
Figure 3. (A) CD25
+
/FoxP3
+
 regulatory T cells subsets were measured by flow cytometry in 
total CD4
+
 splenocytes from WT, CD28 KO and CD28 KI mice expression upon Treg 
stimulation conditions (CD3/CD28 beads + IL-2 + TGF-). (B) Under same stimulation 
condititions, CD25
+
 effector T cells were measured by flow cytometry in CD4
+
 splenocytes 
from WT, CD28 KO and CD28 KI mice expression upon Treg stimulation conditions (* P< 
0.05 compared to KO). 
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Figure 4. The response of mice to Coxiella burnetii infection. (A) Mice were infected with 
5x10
5
 C. burnetii via i.p. route and blood (200 µl), liver (25 mg) and spleen (10 mg) from 
WT, CD28 KO and CD28 KI mice were collected at day 14 post-infection. DNA was 
extracted in a 100µl final volume and the presence of C. burnetii was determined by qPCR 
using a 5 µl DNA extract. Results represented the number of DNA copies for 5 µl DNA 
extract and were expressed as mean ± SD, n = 5 for each group of mice. *,  P value < 0.05. 
(B) IgG response in WT, CD28 KO and CD28 KI mice. Whole blood specimens were 
sampled by retro-orbital puncture where serum was collected at 14 and 21 days post-
inoculation. The presence of IgG directed against C. burnetii was assessed by 
immunofluorescence. The results as titers are expressed as mean ± SD (n = 5 for each group 
of mice and per time point). * P < 0.05. 
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